Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Hepatocellular 37Liver Neoplasms 20Neoplasms 17Leukemia, Myeloid, Acute 13Neoplasm Metastasis 11Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Breast Neoplasms 6Brain Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Prostatic Neoplasms 5Multiple Myeloma 5Lung Neoplasms 5Kidney Neoplasms 5Recurrence 4Glioblastoma 4Colorectal Neoplasms 4Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Leukemia, Promyelocytic, Acute 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Leukemia, Eosinophilic, Acute 3

Interventions

AZD 6244 2pirfenidone 1cabozantinib 1Sorafenib 1Pharmacokinetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neurofibroma, Plexiform × Sorafenib × Clear all
NCT00727233 2019-12-12

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
9 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡